High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

@article{Horio2011HighRR,
  title={High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers},
  author={Akiyo Horio and Takashi Fujita and Hironori Hayashi and Masaya Hattori and Naoto Kondou and Mai Yamada and Eri Adachi and Aya Ushio and Naomi Gondou and Aiko Sueta and Yasushi Yatabe and Hiroji Iwata},
  journal={International Journal of Clinical Oncology},
  year={2011},
  volume={17},
  pages={131-136}
}
BackgroundFive randomized trials of adjuvant trastuzumab have reported significant improvements in recurrence-free survival (RFS) and overall survival. However, patients with node-negative tumors 1 cm or smaller were excluded from these trials. We assessed the recurrence risk and benefit of adjuvant therapy in such patients with small tumors.MethodsWe identified patients with node-negative breast tumors 1 cm or smaller between April 2003 and December 2007. Patients were categorized according to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis

  • Journal of Cancer Research and Clinical Oncology
  • 2013
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Targeted therapeutic options and future perspectives for HER2-positive breast cancer

Jiani Wang, Binghe Xu
  • Signal Transduction and Targeted Therapy
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

calling into question the concept of reversibility

ML Telli, SA Hunt, cardiotoxicity Carlson RW et al Trastuzumabrelated
  • J Clin Oncol 25:3525–3533 Int J Clin Oncol
  • 2012
VIEW 1 EXCERPT

cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

TT Purmonen, E Pankalainen, Finland Turunen JH et al Shortcourse adjuvant trastuzumab in
  • Acta Oncol 50:344–352 136 Int J Clin Oncol
  • 2012
VIEW 1 EXCERPT

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 1 EXCERPT

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 1 EXCERPT

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 3 EXCERPTS